MoonLake Immunotherapeutics AG clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   IZAR-2 · Sonelokimab · Active Psoriatic Arthritis and Anti-TNFα…IZAR-2 · Sonelokimab · Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

   Enrollment closed, study ongoing

   Also in this update: Completion pushed from Jan 15, 2027 to Sep 13, 2027

   MoonLake Immunotherapeutics AG·Phase 3· NCT06641089· Registry history of NCT06641089 on ClinicalTrials.gov (opens the registry)

   Updated Oct 9, 2026

2. Minor

   IZAR-1 · Sonelokimab · Active Psoriatic Arthritis Naive to…IZAR-1 · Sonelokimab · Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

   Primary completion date changed from estimate of Feb 4, 2027 to May 28, 2026

   MoonLake Immunotherapeutics AG·Phase 3· NCT06641076· Registry history of NCT06641076 on ClinicalTrials.gov (opens the registry)

   Updated Oct 9, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.